Epitope profile of CR cells and BM cells
. | CR cells . | BM cells . |
|---|---|---|
| CD10 | 21 ± 23 | 9.9 ± 10 |
| CD31 | 0.8 ± 0.5 | 0.6 ± 0.3 |
| CD34 | 0.6 ± 0.2 | 0.4 ± 0.5 |
| CD44 | 93 ± 5.4 | 74 ± 30 |
| CD45 | 0.6 ± 0.4 | 0.7 ± 0.5 |
| CD54* | 48 ± 2.0 | 15 ± 9.8 |
| CD90 | 99 ± 1.0 | 92 ± 13 |
| CD105 | 95 ± 6.0 | 74 ± 41 |
| CD106* | 50 ± 21 | 15 ± 3.9 |
| CD117 | 0.8 ± 0.1 | 0.7 ± 0.3 |
| CD147 | 99 ± 1.0 | 95 ± 6.7 |
| CD166 | 74 ± 32 | 68 ± 45 |
| Flk-1 | 1.3 ± 0.4 | 1.2 ± 0.4 |
| NGFR | 14 ± 19 | 6.9 ± 7.6 |
. | CR cells . | BM cells . |
|---|---|---|
| CD10 | 21 ± 23 | 9.9 ± 10 |
| CD31 | 0.8 ± 0.5 | 0.6 ± 0.3 |
| CD34 | 0.6 ± 0.2 | 0.4 ± 0.5 |
| CD44 | 93 ± 5.4 | 74 ± 30 |
| CD45 | 0.6 ± 0.4 | 0.7 ± 0.5 |
| CD54* | 48 ± 2.0 | 15 ± 9.8 |
| CD90 | 99 ± 1.0 | 92 ± 13 |
| CD105 | 95 ± 6.0 | 74 ± 41 |
| CD106* | 50 ± 21 | 15 ± 3.9 |
| CD117 | 0.8 ± 0.1 | 0.7 ± 0.3 |
| CD147 | 99 ± 1.0 | 95 ± 6.7 |
| CD166 | 74 ± 32 | 68 ± 45 |
| Flk-1 | 1.3 ± 0.4 | 1.2 ± 0.4 |
| NGFR | 14 ± 19 | 6.9 ± 7.6 |
The CR cells and BM cells at Passage 0 were harvested 14 days after plating and labeled with antibodies against human antigens CD10, CD31, CD34, CD44, CD45, CD54 (ICAM-1), CD90 (Thy-1), CD105 (endogrin, SH2), CD117 (c-kit), CD147, CD166 (ALCAM, SB-10), Flk-1 (VEGF receptor 2), and NGFR (nerve growth factor receptor) and analyzed by flow cytometry. Positive expression was defined as the level of fluorescence greater than 99% of the corresponding isotype-matched control antibodies. All analyses were performed on 5 donors. Positive expression rates (%) are displayed as mean ± SD.
CR cells had a higher expression than the BM cells for CD54 and CD106 (P < .05; 2-factor ANOVA).